</cgi/adclick/?ad=15888&adclick=true&url=http%3A%2F%2Fwww.rocheexchange.com%2Foncology%3Futm_source%3Djco%26utm_medium%3Dbanner%26utm_content%3D728x90%26utm_campaign%3Djco>

Advertisement

Journal of Clinical Oncology </> 	 

	

Search for: 	
	

Limit by: 	
  	Browse by Topic </bbt> or Issue </archive>

</>

Home </> 	Search/Browse </search.dtl> 	Subscriptions </subscriptions>
PDA Services </misc/pda.dtl> 	My JCO </misc/my_jco.dtl> 	Customer
Service </misc/customerservice.dtl>

*Institution: UNIV OF PITTSBURGH, HSLS* | Sign In via User Name/Password
</cgi/login?uri=%2Fmisc%2Fifora.shtml>

/Journal of Clinical Oncology/

Information for Contributors


*MANUSCRIPT CATEGORIES <#Manuscript Categories>*

    * Original Reports <#Original Reports>
    * Review Articles <#Review Articles>
    * Editorials and Comments and Controversies <#Editorials>
    * Special Articles <#Special Articles>
    * Biology of Neoplasia <#Biology of Neoplasia>
    * Diagnosis in Oncology <#Diagnosis in Oncology>
    * The Art of Oncology: When the Tumor Is Not the Target <#Art of
      Oncology>
    * Correspondence <#Correspondence> 

*MANUSCRIPT SUBMISSION REQUIREMENTS*** <#MANUSCRIPT SUBMISSION
REQUIREMENTS>

*REVIEW SERIES <#REVIEW SERIES> *

*DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST <#DISCLOSURES OF
POTENTIAL CONFLICTS OF INTEREST> *

*AUTHORSHIP CONTRIBUTIONS <#AUTHORSHIP CONTRIBUTIONS> *

*CLINICAL TRIALS <#CLINICALTRIALS> *

*CLINICAL TRIAL REGISTRATION <#CLINICALTRIALREGISTRATION> *

*STATISTICAL GUIDELINES <#STATISTICAL>*

	*MANUSCRIPT PREPARATION GUIDELINES <#MANUSCRIPT PREPARATION GUIDELINES>*

    * Title Page <#Title Page>
    * Abstract <#Abstract>
    * Text <#Text>
    * References <#References>
    * Reference Style <#Reference Style>
    * Figures <#Figures>
    * Tables <#Tables>
    * Appendices/Acknowledgements <#Appendices>
    * Use of English Language <#EnglishLanguage> 

*POST-ACCEPTANCE INFORMATION <#POSTACCEPTANCE INFORMATION>*

    * Copyright Form <#Copyright Form>
    * NIH Grantees <#NIHGrantees>
    * Page Proofs <#Page Proofs>
    * Reprints <#Reprints>
    * Permissions <#Permissions> 

***CLICK TO DOWNLOAD REQUIRED FORMS** <jco_disclosure_contribution.pdf>*

  *MANUSCRIPT SUBMISSION CHECKLIST <ManuscriptSubmissionChecklist.pdf>*

 

<http://jco.ascopubs.org/misc/Why_Submit.shtml>

The /Journal of Clinical Oncology (JCO)/ is the primary forum of
scientific discourse for the American Society of Clinical Oncology
(ASCO). /JCO/?s goal is to publish the highest quality manuscripts
dedicated to clinical oncology, in print and electronic media. Original
Reports remain the focus of /JCO/, but this scientific communication is
enhanced by selected Editorials, Review Articles, and other articles
that relate to the care of patients with cancer. For manuscript
guideline information for all article types, please refer to /JCO/?s
Manuscript Preparation Guidelines. In addition, authors should refer to
the International Committee of Medical Journal Editors (ICMJE)?s
"Uniform Requirements for Manuscripts Submitted to Biomedical Journals"
for additional advice on appropriate manuscript preparation.

_MANUSCRIPT CATEGORIES_

Original Reports

Original Reports are the primary mode of scientific communication in
/JCO/. The Editor-in-Chief and an Associate Editor generally review
Original Reports. Selected manuscripts are also reviewed by at least two
external peer reviewers, and, when required, a biostatistician. Comments
offered by external reviewers are returned to the author(s) for
consideration.

Manuscript acceptance is based on many factors, including the importance
of the research to the field of oncology, the originality of the work,
the quality of the study, and the priority of the work to /JCO/ and its
readership. Authors should focus on accuracy, clarity, and brevity in
their presentation, and should avoid lengthy introductions, repetition
of data from tables and figures in the text, and unfocused discussions.
Extended patient demographic data should be included in a table, not
listed within the text.

*Original Reports are limited to 3,000 words of body text, excluding the
abstract, references, figures, and tables. These articles are limited to
six total figures and tables, not counting panels within figures or
CONSORT diagrams required for randomized and phase III trials.*
Additional figures or tables should be labeled "online only" in the
legends or next to the titles. All abstracts are strictly limited to 250
words. Titles are to be descriptive, but succinct.

Review Articles

The Editor-in-Chief typically solicits Review Articles. Authors who wish
to submit an unsolicited Review should contact the Editor-in-Chief to
determine the appropriateness of their Review for publication in /JCO/.
All reviews must be clinically oriented (ie, at least half the review
must describe studies that detail human impact, marker effect on
prognosis, or clinical trials).

Address all inquiries to Daniel G. Haller, MD, Editor-in-Chief, at
jco@asco.org <mailto:jco@asco.org>. The corresponding author or a
co-author, rather than a representative of the authors, should make the
inquiry. A detailed explanation of the manuscript concept, along with an
outline of the review, must be included in the inquiry. The outline
should detail what (if any) specific clinical trials or phase trials
would be discussed. Conflict of interest statements for all authors
should also be included with the inquiry. Authors may wish to review
/JCO/ Conflict of Interest forms
<http://jco.ascopubs.org/misc/ifora.shtml#DISCLOSURES%20OF%20POTENTIAL%20CONFLICTS%20OF%20INTEREST>
before submitting a suitability query.

Review Articles will be reviewed in the same manner as Original Reports.
*These articles are limited to 4,500 words of body text, excluding the
abstract, references, figures, and tables. The Editors also suggest a
limit of 150 references.*

Editorials and Comments and Controversies

The Editor-in-Chief may solicit an Editorial to accompany an accepted
manuscript. Editorials unrelated to a specific article should be
submitted to the Comments and Controversies section. Authors who wish to
submit unsolicited Comments and Controversies should contact Daniel G.
Haller, MD, Editor-in-Chief, at jco@asco.org <mailto:jco@asco.org>,
before submission to determine the appropriateness of the topic for
publication in /JCO/. Editorials should be no more than four to five
double-spaced pages.

Special Articles

Special Articles are manuscripts whose content and style do not fall
under the categories of Original Reports or Review Articles. These may
include, but are not limited to, guidelines, summaries of consensus
meetings, and other scholarly communications. Submissions should be
prepared according to /JCO/'s Manuscript Preparation Guidelines
</misc/ifora.shtml#MANUSCRIPT%20PREPARATION%20GUIDELINES>.

Biology of Neoplasia

Review Articles for the Biology of Neoplasia series address timely
topics in the basic science of cancer. Although these contributions are
generally solicited by /JCO/, proposals are also welcome and should be
discussed with Stephen A. Cannistra, MD, Associate Editor, at
cannists@asco.org <mailto:cannists@asco.org>. The Editorial Office will
send manuscript preparation guidelines for this section of /JCO/ upon
solicitation acceptance. Acceptance of Biology of Neoplasia articles is
contingent upon satisfactory peer review.

Diagnosis in Oncology

Case reports with high-resolution images, preferably in color, including
x-rays or scans of characteristic or classic conditions relevant to
oncology, are invited for consideration in the Diagnosis in Oncology
section. Each submission should be accompanied by a brief overview
describing the case, including a concise literature review. There is no
word limit, but the text should not exceed four to five double-spaced
pages. Figures must be described within the text (do not use figure
legends). If using images of patients, remove all identifying patient
information, including names, dates of birth, dates of service, and
patient identification codes. Written consent of each patient (or the
patient?s legal representative) to publish the image must be uploaded
during the submission process as a supplemental file. Consent must be
provided even though all of the identifying details are removed from any
images and text. If your institution does not have a consent form,
please use /JCO/?s consent form
</misc/diagnosis_oncology_release_form.pdf> for your Diagnosis in
Oncology submission. It is your responsibility to comply with applicable
privacy laws and to obtain a HIPAA-compliant patient authorization if
the case report or the image includes individually identifiable health
information.

The Art of Oncology: When the Tumor Is Not the Target

Art of Oncology articles focus on issues of communication, ethics, and
symptom control in the practice of oncology. Text is limited to 3,000
words and generally begins with a short case report to illustrate the
discussion, although a case is not mandatory. No abstracts are needed
for this section. Authors should consult previously published /JCO/ Art
of Oncology pieces to become familiar with the format of these articles.

Correspondence

Correspondence (letters to the Editor) may be in response to a published
article, or a short, free-standing piece expressing an opinion. In rare
instances, unique cases or observations that would not qualify as an
Original Report may be considered. This is not a place to publish
studies that have not undergone peer review; if they are of sufficient
scientific merit, they should be submitted as an Original Report. If the
Correspondence is in response to a published article, the
Editor-in-Chief may choose to invite the article's authors to write a
Correspondence reply.

Correspondence should be no longer than three double-spaced pages in
length. The title page must contain (1) an original succinctly worded
title, which is not the same as a previously published /JCO/ article
title; (2) author list of no more than 20 names (first name, middle
initial, last name); (3) names of the authors? institutions and an
indication of each author?s affiliation; (4) acknowledgments of research
support; (5) name, address, e-mail address, and telephone and fax
numbers of the corresponding author; and (6) disclaimers, if any.

All accepted Correspondence will be published in the online version of
/JCO/, which is the journal of record. The titles and authors of the
Correspondence associated with a particular issue will be listed in that
print issue. At the discretion of the Editor-in-Chief, selected
Correspondence may also appear in the print version.

[Top] <#top>

_MANUSCRIPT SUBMISSION REQUIREMENTS_

Manuscript Submission Checklist <ManuscriptSubmissionChecklist.pdf>

All new manuscripts should be submitted directly to Daniel G. Haller,
MD, Editor-in-Chief, using the online Manuscript Processing System
<http://submit.jco.org>.

Upon manuscript submission, corresponding authors must provide unique
e-mail addresses for all contributing authors. Receipt of manuscripts
will be acknowledged via e-mail. Upon completion of editorial review,
the corresponding author will receive notification of the Editors'
decision, along with instructions for retrieving reviewers? comments, as
appropriate, via e-mail.

Reports on human experimentation will be reviewed in accordance with the
precepts established by the Helsinki Declaration
<http://www.wma.net/e/policy/b3.htm>. Such reports must include a
statement that human investigations were performed after approval by a
local Human Investigations Committee and in accord with an assurance
filed with and approved by the Department of Health and Human Services
where appropriate. These reports must also include a statement that
informed consent was obtained from each participant or each
participant?s guardian.

All manuscripts dealing with recombinant DNA research must include a
description of the physical and biologic containment procedures
practiced, in accord with the National Institutes of Health Guidelines
for Research Involving Recombinant DNA Molecules
<http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html>.

Manuscripts must contain original material. On the title page, authors
should make a statement about the originality of their work and disclose
previous presentations, reports, or publications that contain any
material that appears in the article. If there is a similar or
supplemental publication, the authors should provide a copy for the
Editors? review. This copy should be uploaded as a supplemental file on
the Manuscript Processing System <http://submit.jco.org>. Any previous
publication or closely related work should be appropriately cited.

Proprietary drug names are typically given once, at the first mention of
the generic drug name in the text, and must accompany the generic drug
name. The use of proprietary drug names or devices requires inclusion of
the manufacturer?s name and location. Proprietary names will not be
published in article titles or abstracts; accepted manuscript titles and
abstracts will be modified to contain the generic name only.

[Top] <#top>

_REVIEW SERIES_

In addition to the 30 standard issues of /JCO/ published each year,
/JCO/ publishes one Review issue every other month.

JCO encourages proposals of topics and articles by e-mail to
specialseries@asco.org <mailto:specialseries@asco.org> or through
Suggest a Topic
<http://jco.ascopubs.org/misc/specialseriessuggesttopic.shtml> under the
Special Series section of www.jco.org <http://jco.ascopubs.org>.
Acceptance of any review article is contingent upon satisfactory peer
review. The Review Series may contain sections unrelated to the
discussion topic These sections include, but are not limited to, Biology
of Neoplasia, Diagnosis in Oncology, Art of Oncology, Special Articles,
Comments and Controversies, and Correspondence.

[Top] <#top>

_DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST_

Authors

In compliance with standards established by the ASCO?s Conflict of
Interest Policy </cgi/content/full/24/3/519> (J Clin Oncol 24:519-521,
2006), ASCO?s intent is to promote balance, independence, objectivity,
and scientific rigor in all of its editorial policies related to /JCO/
through the disclosure of financial and other interests, and
identification and management of potential conflicts. The financial
interests or relationships requiring disclosure are outlined in the ASCO
Conflict of Interest Policy </cgi/content/full/24/3/519>. All
contributors to /JCO/ are required to disclose financial and other
relationships with entities that have investment, licensing, or other
commercial interests in the subject matter under consideration in their
article. These disclosures should include, but are not limited to,
relationships with pharmaceutical and biotechnology companies, device
manufacturers, or other commercial entities whose products or services
are related to the subject matter of the submission.

Disclosures of financial interests or relationships involving the
authors must be addressed on the Author Disclosure Declaration form.
Each author must complete a declaration form online with each manuscript
submission. The corresponding author may complete the form online on
behalf of other authors, or authors may complete their own forms and
forward them to the corresponding author. This information will be
entered as part of the online submission process by the corresponding
author, and hard copies of these forms should not be sent to the
Editorial Office. Statements regarding financial support of the research
must be made on the manuscript title page, and disclosed under question
#5 (Research Funding) on the form. This form is available online
<http://jco.ascopubs.org/misc/jco_disclosure_contribution.pdf> or upon
request from the Editorial Office. The Editorial Office recommends that
corresponding authors collect the Author Disclosure Declaration Form
from all other authors before starting the formal, online submission.
All disclosures will appear in print at the end of all published articles.

Principal Investigator Restrictions

For reports based on clinical trials that began accrual on or after
April 29, 2004, the ASCO Conflict of Interest Policy
</cgi/content/full/24/3/519> places some restrictions on the financial
relationships of Principal Investigators (PIs). If a PI holds any
relationships that are restricted by the Policy, his or her manuscript
may require an exception to the ASCO Conflict of Interest Policy
</cgi/content/full/24/3/519> in order to be considered for publication.

For more information, please see the ASCO Conflict of Interest Policy
</cgi/content/full/24/3/519> (J Clin Oncol 24: 519-521, 2006).

Reviewers and Editors

/JCO/ requires all Editors and reviewers to make similar disclosures.
Reviewers are asked to make disclosures when accepting a review
assignment. Editors? disclosures are published annually
</cgi/data/JCO.2005.05.1714/DC1/1> online, whereas reviewers?
disclosures are held in confidence within the Editorial Office.

Additional help regarding ASCO?s Conflict of Interest Policy can be
found online at ASCO.org.

[Top] <#top>

_AUTHORSHIP CONTRIBUTIONS_

In accordance with the International Committee of Medical Journal
Editors <http://www.icmje.org>, each author should have participated
sufficiently in the work to take public responsibility for the content.
All other contributors who do not meet sufficient criteria for
authorship should be noted in the Acknowledgments section. Corresponding
authors are responsible for ensuring that all authors have seen and
approved the final manuscript prior to submission.

* Author Contribution Forms must be filled out and submitted as part of
every online submission process. These forms should be forwarded to the
corresponding author rather than the Editorial Office.* The forms are
available online </misc/jco_disclosure_contribution.pdf>, or upon
request from the Editorial Office.

[Top] <#top>

_CLINICAL TRIALS_

Results of clinical studies should be supported by a clear description
of the study design, conduct, and analysis methods used to obtain the
results.

Reports of phase II studies should include from the protocol a clear
definition of the primary end point, the hypothesized value of the
primary end point that justified the planned sample size, and a
discussion of possible weaknesses, such as comparison to historical
controls.

Phase I studies will be well received if they have interesting clinical
responses, unusual toxicity that pointed to the mechanism of action of
the agents, and important or novel correlative laboratory studies
associated with the trials.

[Top] <#top>

_CLINICAL TRIAL REGISTRATION_

Any clinical trial for which *patient enrollment begins on or after
November 1, 2006,* must be registered. Authors will have six months from
the first patient enrollment to register the trial, but registration
prior to enrollment is recommended. This registration policy applies to
prospective, randomized, controlled trials only.

The Editors will follow the ICMJE definition of a clinical trial: "Any
research project that prospectively assigns human subjects to
intervention and comparison groups to study the cause-and-effect
relationship between a medical intervention and a health outcome. By
'medical intervention' we mean any intervention used to modify a health
outcome. This definition includes drugs, surgical procedures, devices,
behavioral treatments, process-of-care changes, and the like... a trial
must have at least one prospectively assigned concurrent control or
comparison group in order to trigger the requirement for registration"
(De Angelis CD, Drazen JM, Frizelle FA, et al: Clinical trial
registration: A statement from the International Committee of Medical
Journal Editors. N Engl J Med 351:1250-1251, 2004).

/JCO/ will accept registration in any public database that meets the
World Health Organization's minimal data set. The ICMJE Web site (FAQs)
lists the following registries as fully compliant: www.actr.org.au
<http://www.actr.org.au>, www.clinicaltrials.gov
<http://www.clinicaltrials.gov>, www.controlled-trials.com
<http://www.controlled-trials.com>, www.umin.ac.jp/ctr/index.htm
<http://www.umin.ac.jp/ctr/index.htm>, and www.trialregister.nl
<http://www.trialregister.nl>.

Upon submission, authors are required to provide the registration
identification number and the URL for the trial's registry.

[Top] <#top>

_STATISTICAL GUIDELINES_

In the case of randomized clinical trials, authors should follow closely
the guidelines of the CONSORT <http://www.consort-statement.org/>
statement. Authors must submit a CONSORT diagram with all randomized
studies, but this diagram will not count against the limit of six total
figures and tables.

For randomized clinical trials, two-sided /P/ values should be reported.
If the trial design was Bayesian, used one-sided /P/ values, or was not
based on a standard two-sided test, the primary result and conclusion
may be described in terms of the original design, but the two-sided /P/
value of a standard test must also be included. Actual values of all /P/
values should be reported, and not, for example, /P/ >.05. Two digits
are sufficient for /P/ > .01.

Differences may be reported in terms of odds ratios or hazard ratios,
but there should also be a comparison of an absolute difference of the
primary measure (eg, difference in survival at five years or difference
in proportions of successes).

When studies report prognostic markers (based on clinical, etiologic, or
genetic factors), highest priority will be given to studies for which an
algorithm obtained in a training set is applied exactly the same way in
the validation set as in the training set (ie, the factors included and
the cutoffs must be determined in the training set and applied to each
patient in the validation set). Further fine-tuning should be identified
clearly as exploratory. Prognostic studies that report the results of an
algorithm from the same data that were used to fit the algorithm will
have lower priority, but will be enhanced by the inclusion of
cross-validation analyses and a clear statement of the limitations of
the study.

Reports describing data from multiple studies will be considered to be a
true meta-analysis only if the data were analyzed separately and an
attempt was made to include study data that were not reported. Studies
that apply meta-analytic techniques to published data will have lower
priority, and authors should include a discussion of the limitations.

Reports of studies with multiple or secondary end points should address
the multiple comparison issues and describe the exploratory nature of
the studies.

[Top] <#top>

_MANUSCRIPT PREPARATION GUIDELINES_

Download the Author Disclosure Declaration and Contribution Forms
</misc/jco_disclosure_contribution.pdf>.

Title Page

The first page of the manuscript must contain the following information:
(1) succinct title of the report; (2) author list of 20 or fewer names
(first name, middle initial, last name); (3) names of each author?s
institutions and an indication of each author's affiliation; (4)
acknowledgments of research support; (5) name, address, telephone and
fax numbers, and e-mail address of the corresponding author; (6) running
head of fewer than 65 characters (including spaces); (7) list of where
and when the study has been presented in part elsewhere, if applicable;
and (8) disclaimers, if any.

Abstract

*Abstracts are limited to 250 words and must appear after the title
page.* Abstracts must be formatted according to the following headings:
(1) PURPOSE, (2) PATIENTS AND METHODS (or MATERIALS AND METHODS,
METHODS, or similar heading), (3) RESULTS, and (4) CONCLUSION. Authors
may use DESIGN instead of PATIENTS AND METHODS in abstracts of Review
Articles. Proprietary or trade names may not be used in the title or
abstract. Comments and Controversies, Editorials, Correspondence, Art of
Oncology, and Diagnosis in Oncology articles do not require abstracts.

Text

*The body of the manuscript should be written as concisely as possible
and must not exceed the manuscript category word limits described
herein. All pages of a submission should be numbered and double spaced.
Helvetica and Arial at 12 pt size are the recommended fonts for all text
(see Figures section for acceptable fonts for figures)*. /JCO/ adheres
to the style guidelines set forth by the ICMJE <http://www.icmje.org>.

References

References must be listed and numbered after the body text in the order
in which they are cited in the text. They should be double spaced and
should appear under the heading ?REFERENCES.? Abbreviations of medical
periodicals should conform to those used in the latest edition of Index
Medicus and on MEDLINE. The "List of Journals Indexed in Index Medicus"
<http://www.nlm.nih.gov/tsd/serials/lji.html> includes the latest
abbreviations. Inclusive page numbers must be cited in the reference.
When a reference is an abstract or supplement, it must be identified as
such in parentheses at the end of the reference. Abstract and supplement
numbers should be provided, if applicable. When a reference is
unpublished data, a manuscript in preparation, or a manuscript submitted
but not in press, it should be included in parentheses in the body of
the text, and not cited in the reference list. Personal communications
should also be listed parenthetically and should contain the first
initial and last name of the contact as well as the month and year of
the communication. Published manuscripts and manuscripts that have been
accepted and are pending publication should be cited in the reference list.

Reference Style

/Journal article with one, two, or three authors:/
1. Dolan ME, Pegg AE: O6-Benzylguanine and its role in chemotherapy.
Clin Cancer Res 8:837-847, 1997

/Journal article with more than three authors:/
2. Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneous T-cell
lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87:893-899, 1996

/Journal article in press (manuscript has been accepted for publication):/
3. Scadden DT, Schenkein DP, Bernstein Z, et al: Combined immunotoxin
and chemotherapy for AIDS-related non-Hodgkin's lymphoma. Cancer (in press)

/Supplement:/
4. Brusamolino E, Orlandi E, Morra E, et al: Analysis of long-term
results and prognostic factors among 138 patients with advanced
Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
Ann Oncol 5:S53-S57, 1994 (suppl 2)

/Book with a single author:/
5. Woodruff R: Symptom Control in Advanced Cancer. Victoria, Australia,
Asperula Pty Ltd, 1997, pp 65-69

/Book with multiple authors:/
6. Iverson C, Flanagin A, Fontanarosa PB, et al: American Medical
Association Manual of Style (ed 9). Baltimore, MD, Williams & Wilkins, 1998

/Chapter in a multiauthored book with editors:/
7. Seykora JT, Elder DE: Common acquired nevi and dysplastic nevi as
precursor lesions and risk markers of melanoma, in Kirkwood JM (ed):
Molecular Diagnosis and Treatment of Melanoma. New York, NY, Marcel
Dekker, 1998, pp 55-86

/Abstract:/
8. Bardia A, Wang AH, Hartmann LC, et al: Physical activity and risk of
postmenopausal breast cancer defined by hormone receptor status and
histology: A large prospective cohort study with 18 years of follow up.
J Clin Oncol 24:49s, 2006 (suppl; abstr 1002)

9. Kaplan EH, Jones CM, Berger MS: A phase II, open-label, multicenter
study of GW572016 in patients with trastuzumab refractory metastatic
breast cancer. Proc Am Soc Clin Oncol 22:245, 2003 (abstr 981)

/Conference/meeting presentation:/
10. Dupont E, Riviere M, Latreille J, et al: Neovastat: An inhibitor of
angiogenesis with anti-cancer activity. Presented at the American
Association of Cancer Research Special Conference on Angiogenesis and
Cancer, Orlando, FL, January 24-28, 1998

/Internet resource:/
11. Health Care Financing Administration: Bureau of data management and
strategy from the 100% MEDPAR inpatient hospital fiscal year 1994: All
inpatients by diagnosis related groups, 6/95 update.
http://www.hcfa.gov/a1194drg.txt

/Digital Object Identifier (DOI):/
12. Small EJ, Smith MR, Seaman JJ, et al: Combined analysis of two
multicenter, randomized, placebo-controlled studies of pamidronate
disodium for the palliation of bone pain in men with metastatic prostate
cancer. J Clin Oncol 10.1200/JCO.2003.05.147

/Government Announcement/Publication:/
13. Miller BA, Ries CAG, Hankey BF, et al (eds): Cancer Statistics
Review: 1973-1989. Bethesda, MD, National Cancer Institute, NIH
publication No. 92-2789, 1992

/ASCO Educational Book:/
14. Benson AB III: Present and future role of prognostic and predictive
markers for patients with colorectal cancer. Am Soc Clin Oncol Ed Book
187-190, 2006

Figures

Figures must be cited in the order they appear in the text using Arabic
numerals. Figure legends should appear within the document in a separate
section just before the references. Figure legends are required for all
article types, with the exception of Diagnosis in Oncology articles, and
should be double spaced in the manuscript. All relevant and explanatory
information extraneous to the actual figure, including figure part
labels, footnotes, abbreviations, acronyms, arrows, and levels of
magnification in insets, should be defined in the legend text. Figure
legends must not exceed 55 words per figure.

/JCO/ prints figures at 1-column, 1.5-column, or 2-column width.
One-column figures measure 3.5 inches (8.5 cm), 1.5-column figures
measure 5 inches (12.5 cm), and 2-column figures measure 6.75 inches in
width (17 cm). Submit figures at 100% size whenever possible.

For first submission of figures, please follow these guidelines:

Images embedded in word processing files will generally, but not always,
yield good results. If an image must be embedded in the flow of the
document and it is not converting correctly, it is best to create a PDF
and submit that instead of the original source file.

Images may be embedded in PowerPoint files, and PowerPoint files may be
submitted for conversion, as long as each file contains a single slide.
Multi-slide files cannot be converted to a PDF.

For maximum satisfaction with the results of image conversion, try
submitting a PDF that you have created. Creation of this file will help
you to determine exactly how the image will appear during the
peer-review process.

Formats accepted on first submission are .eps, .gif, .tiff, .jpeg, and
PowerPoint. Formats that are not supported include the following: any
file using OLE (Object Linking and Embedding) technology to display
information or embed files, Bitmap (.bmp), PICT (.pict), Excel (.xls),
Photoshop (.psd), Canvas (.cnv), CorelDRAW (.cdr), Illustrator (.ai),
and locked or encrypted PDFs. Images will be converted to PDFs and
appended to the manuscript file. If images are included within the
manuscript file, they do not need to be uploaded separately.

For submission of figures upon acceptance, please follow these guidelines:

Submit all line graphs, bar graphs, flow charts, scatter plots, forest
plots, diagrams, and gene expressions as vector-based artwork, not
bitmapped art (ie, no .bmp, .tiff, .gif, or .jpeg). Vector artwork
should be submitted as .eps or PDF files whenever possible, but original
documents from applications that are widely available (Adobe
Illustrator, Microsoft Word, PowerPoint, or Excel) are also usable. If
the graph must be submitted as a bitmap, please submit a 300 dpi .tiff
or high-quality .jpeg at 100% scale.

All typeface used within the figures should be 6 pt to 12 pt Univers
(Arial or Helvetica are also acceptable), and .eps files with fonts
embedded (not converted to paths) are preferred.

Photographs (halftones) must have a minimum resolution of 300 dpi at
final size (100% scale). Figure parts should not have figure numbers or
letters embedded in the photographs. Labels may be placed on top of the
image or set outside of each part. Labels may also be listed in figure
legends.

Upon acceptance of a manuscript, a graphic artist will format all
figures to /JCO/ style.

Tables

Tables must be cited in the order in which they appear in the text using
Arabic numerals. The table?s legend may include any pertinent notes and
must include definitions of all abbreviations and acronyms that have
been used in the table. Tables submitted with multiple parts will be
renumbered.

Appendices/Acknowledgments

Acknowledgments longer than 45 words and all appendices will be
published in the online version of /JCO/. A reference to the
availability of the online material will appear in the print version of
the article.

Use of English Language

Appropriate use of the English language is a requirement for publication
in /JCO/. Authors who have difficulty writing in English may seek
assistance with grammar and style to improve the clarity of their
manuscript. Many companies provide substantive editing via the Web,
including: www.biosciencewriters.com <http://www.biosciencewriters.com>;
www.bostonbioedit.com <http://www.bostonbioedit.com>;
www.sciencedocs.com <http://www.sciencedocs.com>; www.prof-editing.com
<http://www.prof-editing.com>; www.journalexperts.com
<http://www.journalexperts.com>; www.bluepencilscience.com
<http://www.bluepencilscience.com> and www.stallardediting.com
<http://www.stallardediting.com>. Please note that neither ASCO nor
/JCO/ takes responsibility for, or endorses, these services. Their use
does not guarantee acceptance of a manuscript for publication.

[Top] <#top>

_POST-ACCEPTANCE INFORMATION_

Copyright Form

Manuscripts will not be published until each author has completed the
copyright form. Upon acceptance of the manuscript, each author will
receive an e-mail invitation to sign a statement confirming that the
manuscript contains no material for which publication would violate any
copyright or other personal or proprietary right of any person or
entity. US Federal employees will complete a separate section on the
copyright form.

NIH Grantees

The publisher grants the author permission to provide a copy of the
accepted manuscript to the National Institutes of Health upon the
manuscript's acceptance for publication, with the public release to
PubMed Central 12 months after final print publication of the article in
/JCO/.

Page Proofs

Corresponding authors will receive proofs and must carefully review them
for data and typesetting errors. When proofs are available for
downloading, the corresponding author will receive an e-mail
notification with a password and Web address from which PDF proofs can
be downloaded and printed. Paper copies will not be sent.

Corrections to proofs must be returned by e-mail, fax, or mail within 48
hours. The corresponding author is responsible for collecting and
submitting all author corrections into a single submission. Publication
may be delayed if proofs are not returned by the publisher?s deadline.
The Editor-in-Chief must approve all major alterations, which may delay
publication of the manuscript.

Reprints

An order form showing the cost of reprints accompanies the page proofs
so that authors may order reprints before publication. /All reprints
will be printed in color at no additional charge to the author/.
Reprints may be ordered after publication, but at a higher cost. In
addition to the opportunity to purchase high-quality paper reprints,
authors will be given 10 electronic reprints at no charge. These
e-prints may be distributed via e-mail to colleagues, regardless of
whether the recipients are JCO subscribers.

Permissions

Authors submit manuscripts with the understanding that if accepted, the
copyright of the article, including the right to reproduce the article
in all forms and media, shall be assigned exclusively to ASCO.

If any portion (eg, a figure or table) of a manuscript submitted for
consideration has been published previously, the original source must be
acknowledged, and written permission from the copyright holder to
reproduce the material must be submitted. Permission is required
regardless of authorship or publisher except for documents in the public
domain. An outgoing permission template <outgoing_permissions_form.pdf>
can be found online.

Upon submission, authors are required to upload these permission
statements from the copyright holder using the Manuscript Processing
System <http://submit.jco.org>. The accepted manuscript will not be
published if the necessary permissions have not been granted.

ASCO will not refuse any reasonable request for permission to reproduce
any contributions published in/JCO/. Authors should e-mail requests to
permissions@asco.org <mailto:permissions@asco.org>.

[Top] <#top>

About
JCO </misc/About.shtml> 		Editorial
Roster </misc/edboard.shtml> 		Advertising
Information </misc/iforadvertisers.shtml> 		Librarians &
Institutions </misc/librarians.dtl> 		Rights &
Permissions </misc/permissions.shtml> 		Site Map </misc/site.shtml>

Copyright </misc/terms.shtml> © 2007 by the American Society of Clinical
Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use </misc/Terms_and_Cond.shtml>
  	HighWire Press 	HighWire Press? <http://highwire.stanford.edu>
assists in the publication of JCO Online 	 

 

